Observational studyRevista da Associacao Medica Brasileira (1992)2026
Teratogenic risk of carbamazepine, levetiracetam, and lamotrigine treatment in pregnant women with epilepsy.
Observational study in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAntiseizure medications used during pregnancy may exert teratogenic effects on the developing fetus, with risks varying according to drug type, dosage, and exposure timing. While older agents such as carbamazepine are associated with known risks, newer agents including lamotrigine and levetiracetam have demonstrated more favorable safety profiles. This study aimed to evaluate pregnancy outcomes, major congenital malformation rates, and seizure frequency in pregnant women with epilepsy exposed to carbamazepine, lamotrigine, or levetiracetam as monotherapy or polytherapy, compared with an untreated control group.
methodsThis retrospective observational study included pregnant women with epilepsy who were categorized into antiseizure medication-exposed (monotherapy or polytherapy) and non-exposed groups. Clinical data, including seizure history, medication type and dosage, pregnancy outcomes, and neonatal findings, were collected. major congenital malformations were identified according to European Surveillance of Congenital Anomalies criteria.
resultsA total of 307 pregnancies were analyzed, resulting in 276 live births. major congenital malformation rates were 6.1% for carbamazepine, 1.7% for levetiracetam, and 3.6% for lamotrigine monotherapy. Polytherapy outcomes varied by combination, with relatively low risks observed in levetiracetam-containing regimens. Seizure frequency remained unchanged in most cases (69.6%), increased in 21%, and decreased in 9.4% of pregnancies. Preconception seizure presence significantly increased the risk of seizures during pregnancy.
conclusionLevetiracetam and lamotrigine demonstrate favorable safety profiles, whereas carbamazepine carries a moderate teratogenic risk. Polytherapy risk is combination-dependent, and preconception seizure control is a key predictor of seizure outcomes during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.